⭐️Phenotypes of AKI from monoclonal gammopathy
⭐️ Data suggest that patients with MGRS are at high risk for progression to kidney failure if not treated with clone-directed therapy (e.g., bortezomib)
Read more about it in the section "Monoclonal Gammopathies and AKI" ⬇️
⭐️Other etiologies of AKI in cancer
Hypercalcemia
Direct kidney parenchymal infiltration
Obstruction⬇️
⭐️Conventional chemoRx toxicities ⬇️
Prototype chemoRX AKI from Cisplatin : Mediated by apoptosis, inflammation, DNA and mitochondrial injury ⬇️
HSCT associated AKI
The flowchart sums it all ⬇️
AKI from targeted therapies.
check out the table which summarizes it. ⬇️
A brief synopsis of AKI from
-ImmunoRx
-CellularRx (CAR-T cell)
-TMA
-Hemodynamic causes
-TLS⬇️
To conclude
⭐️Precision medicine : need to have biomarkers to predict AKI on oncoRx agents
⭐️eg: CRP and urinary retinol binding protein in ICPi-AKI induced AIN
⭐️Can help to identify pseudo-AKI which can happen with drugs like PARP & CDK 4/6 inhibitors
🔥Our editorial speaks about the summary of the individual topics.
Paraproteinemia
TMA $
Na/K ⬇️⬆️in Ca
Palliative Rx
HSCT & kidney
Heme cancer & kidney
Paraneoplastic GN
Sickle cell ds
OncoSx and AKI
Anemia & cancer
Anti Ca Rx dosing in CKD
TxP Onconeph